Core Insights - The Québec government has decided to expand coverage for Dexcom Continuous Glucose Monitoring (CGM) Systems under the Régie de l'assurance maladie du Québec (RAMQ) for eligible individuals aged 18 and older with type 2 diabetes on intensive insulin therapy [1] Group 1: Company Overview - Dexcom, Inc. is recognized as a global leader in glucose biosensing technology [1] - The expansion of coverage is expected to enhance access to CGM systems for a significant number of patients in Québec [1] Group 2: Industry Context - Type 2 diabetes is the most prevalent form of diabetes, affecting nearly 90% of individuals with the condition according to Diabète Québec [1] - The decision by the Québec government reflects a growing recognition of the importance of continuous glucose monitoring in managing diabetes effectively [1]